Clinical trials: Irritable Bowel Syndrome - Diarrhoea
Diarrhea- Predominant Irritable Bowel Syndrome, Quality of Life
Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome
The aim of this study is to evaluate the effects of Mesalamine and Amitriptyline drugs on the Quality of Life and Symptom Severity Scale in patients with Diarrhea- Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- NCT02190526
- Testing
- Mesalazine(asacol 800 mg), Amitriptyline
- Where
- Iran
- Sponsor
- Tehran University of Medical Sciences
Irritable Bowel Syndrome
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT04655599
- Testing
- Olorinab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Irritable Bowel Syndrome With Diarrhea
Eluxadoline Bile Acid Malabsorption (BAM) Study
This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
- Trial name
- NCT03441581
- Testing
- Eluxadoline
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Allergan
Irritable Bowel Syndrome
Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS.
- Trial name
- NCT01786109
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Michael Camilleri
Diarrhea-predominant Irritable Bowel Syndrome
Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg
Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea.
- Trial name
- NCT01358708
- Testing
- LACTEOL® 340 mg
- Where
- 8 sites in France, Germany
- Volunteers
- 26 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome-bile Acid Diarrhea
A Study of Hemp Hull WFI for IBS Diarrhea
The purpose of this study is the effect of a study bar, which contains 15 grams of insoluble dietary fiber total sourced from Hemp hulls, on intestinal permeability in irritable bowel syndrome (IBS)-bile acid diarrhea individuals.
- Trial name
- NCT06028035
- Testing
- BB01
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI)
A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.
The goal of this clinical trial is to learn if oral lyophilized fecal microbiota therapy (ORAL-LYO-FMT) helps treat diarrhea-predominant irritable bowel syndrome (IBS-D) and prevent the recurrence of Clostridioides difficile…
- Conditions
- Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D), Recurrent Clostridioides Difficile Infection (rCDI), Fecal Microbiota Therapy (FMT), Irritable Bowel Syndrome (IBS)
- Trial name
- ORAL-LYO-FMT (NCT06948461)
- Testing
- ORAL-LYO-FMT
- Volunteers
- 63 people
- Sponsor
- PharmaPlanter Technologies Inc
Small Intestinal Bacterial Overgrowth, SIBO
The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms
The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT06317441
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Nimble Science Ltd.
Irritable Bowel Syndrome With Diarrhea
A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
This study will evaluate the effects of ORP-101 versus placebo on stool consistency and abdominal pain in patients with Irritable Bowel Syndrome with Diarrhea (IBS-D).
- Trial name
- NCT04129619
- Testing
- ORP-101
- Where
- 74 sites in United States
- Volunteers
- 321 people
- Sponsor
- OrphoMed, Inc.
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea
The purpose of this study is to evaluate the efficacy as well as safety of rifaximin combined fecal microbiota transplantation(Gut microbiota reconstruction) in the treatment of IBS-D.
- Trial name
- NCT02651740
- Testing
- Rifaximin, Fecal microbiota transplantation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Zhongshan Hospital
Irritable Bowel Syndrome, Diarrhea- Irritable Bowel Syndrome
To Study the Effect of Short-chain Fructooligosaccharides in Women With Irritable Bowel Syndrome
To evaluate whether there is clinical improvement through the scales (Bristol, IBS severity score, and IBS quality of life) in women with irritable bowel syndrome after administration of SC-FOS (short-chain…
- Conditions
- Irritable Bowel Syndrome, Diarrhea- Irritable Bowel Syndrome, Constipation-predominant Irritable Bowel Syndrome
- Trial name
- NCT05941650
- Testing
- Short Chain Fructooligosaccharides, Corn Starch
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de Chihuahua
Diarrhea-predominant Irritable Bowel Syndrome
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
To demonstrate the superiority of YM060 to a placebo in global assessment of relief of overall IBS symptoms and stool form normalization, and to evaluate safety in female patients with diarrhea-predominant irritable bowel…
- Trial name
- NCT01870895
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 577 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhea
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) carries a high prevalence worldwide and imposes substantial economic burden on patients, healthcare systems and society.
- Trial name
- NCT03557788
- Testing
- Rifaximin Oral Tablet
- Where
- Singapore
- Volunteers
- 33 people
- Sponsor
- National University Hospital, Singapore
Irritable Bowel Syndrome
Pinaverium and Herbs for Irritable Bowel Syndrome Treatment: an Onset and Offset Study (PHIBEST)
The purpose of this study is to test the onset of action, offset of action, efficacy, and safety of pinaverium and an herbal medication for irritable bowel syndrome (IBS) for a long term (over one year).
- Trial name
- NCT02330029
- Testing
- Pinaverium, Atractylodes, Paeonia Lactiflora
- Where
- 4 sites in China
- Volunteers
- 800 people
- Sponsor
- Macrohard Institute of Health
Irritable Bowel Syndrome
Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide
A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.
- Trial name
- NCT01678781
- Where
- 24 sites in China, Egypt and 2 more
- Volunteers
- 607 people
- Sponsor
- Abbott
Irritable Bowel Syndrome with Diarrhea, Purine Metabolism Disorder
B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis
This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method.
- Trial name
- NCT06612411
- Testing
- B. subtilis, Dead B. subtilis
- Where
- 2 sites in China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Jinling Hospital, China
Diarrhea
Assessment of Elemental Impurities Level After Multiple Administration of DWJ1230 or DWB2001 in Subjects With Functional Diarrhea or Irritable Bowel Syndrome With Predominant Diarrhea.
This study aims to assess elemental impurities level after dministration of dioctahedral smectite in subjects with functional diarrhea or irritable bowel syndrome with predominant diarrhea.
- Trial name
- NCT05816681
- Testing
- DWJ1230, DWB2001
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome
Irritable bowel syndrome is characterized by the presence of chronic, recurrent abdominal pain, alterations in bowel habits, and abdominal distension. The medical diagnosis is made using the Rome IV criteria.
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Mixed
- Trial name
- NCT07103772
- Testing
- Ananá
- Where
- Mexico
- Volunteers
- 94 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed
Faecal Microbiota Transplantation in Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is the most common functional bowel disorder, being present in approximately 10% of adult Europoid population. The etiology of IBS is elusive.
- Trial name
- MISCEAT (NCT04899869)
- Testing
- Faecal microbiota transplantation with active study microbiota first, Faecal microbiota transplantation with inactive autoclaved study microbiota first, Faecal microbiota transplantation with inactive autoclaved study microbiota only
- Where
- Czechia
- Volunteers
- 61 people
- Sponsor
- Thomayer University Hospital